ATE444308T1 - Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon - Google Patents

Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon

Info

Publication number
ATE444308T1
ATE444308T1 AT03711002T AT03711002T ATE444308T1 AT E444308 T1 ATE444308 T1 AT E444308T1 AT 03711002 T AT03711002 T AT 03711002T AT 03711002 T AT03711002 T AT 03711002T AT E444308 T1 ATE444308 T1 AT E444308T1
Authority
AT
Austria
Prior art keywords
fusion proteins
humanized
specific antibodies
antibodies
disclosed
Prior art date
Application number
AT03711002T
Other languages
English (en)
Inventor
Christoph Renner
Andrew Scott
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE444308T1 publication Critical patent/ATE444308T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03711002T 2002-02-13 2003-02-12 Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon ATE444308T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35583802P 2002-02-13 2002-02-13
PCT/US2003/004243 WO2003068924A2 (en) 2002-02-13 2003-02-12 Fusion proteins of humanized g250 specific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
ATE444308T1 true ATE444308T1 (de) 2009-10-15

Family

ID=27734567

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03713430T ATE509032T1 (de) 2002-02-13 2003-02-12 Chimerizierte gm-csf antikörper
AT03711002T ATE444308T1 (de) 2002-02-13 2003-02-12 Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03713430T ATE509032T1 (de) 2002-02-13 2003-02-12 Chimerizierte gm-csf antikörper

Country Status (8)

Country Link
US (5) US7381801B2 (de)
EP (2) EP1507859B1 (de)
JP (1) JP2006500905A (de)
AT (2) ATE509032T1 (de)
AU (2) AU2003215188A1 (de)
DE (1) DE60329489D1 (de)
ES (1) ES2365606T3 (de)
WO (2) WO2003068924A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
KR101205289B1 (ko) 2004-07-02 2012-11-27 빌렉스 아게 Ｇ-250 발현 종양의 개선된 보조제 요법
BRPI0608281B8 (pt) * 2005-04-18 2021-05-25 Amgen Res Munich Gmbh anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende
RU2447085C2 (ru) * 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
AU2013201228B2 (en) * 2006-02-08 2016-01-21 Eisai, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
US7741450B2 (en) * 2006-02-08 2010-06-22 Morphotek Inc. Antibodies to GM-CSF
WO2008063898A2 (en) * 2006-11-08 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
EP2101780B1 (de) 2006-11-21 2013-10-09 Kalobios Pharmaceuticals, Inc. Verfahren zur behandlung chronischer entzündungskrankheiten mithilfe eines gm-csf-agonisten
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
CN101687926A (zh) * 2007-05-23 2010-03-31 哮喘和气道Crc有限公司 中和抗体
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN104072613A (zh) * 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
US20090181020A1 (en) * 2008-01-15 2009-07-16 Kalobios Pharmaceuticals, Inc. Methods of Treating Bone-Loss Disorders Using a GM-CSF Antagonist
EP2282757B1 (de) * 2008-04-07 2013-05-22 Kalobios Pharmaceuticals, Inc. Neutralisation von gm-csf zur behandlung von herzversagen
WO2009134805A2 (en) * 2008-04-28 2009-11-05 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
JP2011526792A (ja) * 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質
WO2010009987A2 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
EP2328930B1 (de) * 2008-08-20 2014-12-24 Probiodrug AG Gegen das pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe) gerichtete antikörper
CN102271705A (zh) 2008-12-22 2011-12-07 墨尔本大学 骨关节炎治疗
CA2747206C (en) 2008-12-22 2018-04-24 The University Of Melbourne Pain treatment
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
US8609101B2 (en) 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
ES2952394T3 (es) 2010-07-29 2023-10-31 Buzzard Pharmaceuticals AB Antagonistas quiméricos del receptor IL-1 de tipo I
CN103827143A (zh) 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
WO2013120060A1 (en) 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
EP2968468B1 (de) 2013-03-13 2021-07-14 Buzzard Pharmaceuticals AB Chimäre zytokine formulierungen zur okularen verabreichung
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
US9714953B2 (en) 2014-04-04 2017-07-25 Autotelic Llc Methods, devices, and reagents for monitoring paclitaxel concentration in plasma for pharmacokinetic-guided dosing of paclitaxel
KR20160144416A (ko) * 2014-04-04 2016-12-16 오토텔릭 엘엘씨 파클리탁셀의 약물동태-유도된 투여를 위해 혈장 중의 파클리탁셀 농도를 모니터링하는 방법, 장치 및 시약
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
AU2018345751A1 (en) 2017-10-02 2020-05-07 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US12344646B2 (en) 2018-12-13 2025-07-01 Bang DING Antibody-TNF α fusion protein and its preparation and applications
US20210284744A1 (en) * 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
EP0366707A1 (de) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoklonale antikörper gegen nierenzellen-karzinom
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
WO1994009149A1 (en) * 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2060741A1 (en) * 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5387676A (en) 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
US6027887A (en) 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US5981711A (en) 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
FR2723462B1 (fr) 1994-08-02 1996-09-06 Thomson Lcd Procede d'adressage optimise d'ecran a cristaux liquides et dispositif pour sa mise en oeuvre
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DK1259547T3 (da) * 2000-03-01 2012-10-15 Medimmune Inc Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体

Also Published As

Publication number Publication date
US7897743B2 (en) 2011-03-01
EP1530580A2 (de) 2005-05-18
US20120029172A1 (en) 2012-02-02
WO2003068924A2 (en) 2003-08-21
US20100167395A1 (en) 2010-07-01
AU2003217386A1 (en) 2003-09-04
JP2006500905A (ja) 2006-01-12
WO2003068920A8 (en) 2004-07-29
WO2003068924A3 (en) 2004-12-29
US20090259027A1 (en) 2009-10-15
ES2365606T3 (es) 2011-10-07
AU2003215188A1 (en) 2003-09-04
EP1507859A4 (de) 2007-05-30
EP1507859A2 (de) 2005-02-23
EP1530580A4 (de) 2006-02-01
US7714113B2 (en) 2010-05-11
AU2003215188A8 (en) 2003-09-04
ATE509032T1 (de) 2011-05-15
AU2003217386B2 (en) 2008-06-26
EP1507859B1 (de) 2009-09-30
EP1530580B1 (de) 2011-05-11
DE60329489D1 (de) 2009-11-12
US20060045876A1 (en) 2006-03-02
WO2003068920A9 (en) 2004-06-03
US7381801B2 (en) 2008-06-03
WO2003068920A3 (en) 2004-07-01
WO2003068920A2 (en) 2003-08-21
US20040053365A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
ATE444308T1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
WO2005012493A3 (en) Anti-cd19 antibodies
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
ATE385806T1 (de) Fusionsproteine
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
CY1119106T1 (el) Αντισωματα εναντι masp-2
LTPA2016028I1 (lt) Imunoglobulino chimeriniai monomero-dimero hibridai
MY142290A (en) Anti-il-6 antibodies compositions, methods and uses
TW200510459A (en) RG1 antibodies and uses thereof
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
WO2005000901A3 (en) Cd20-specific antibodies and methods of employing same
WO2006099141A3 (en) Anti-mesothelin antibodies
NZ577828A (en) Human antibodies that bind human il-12 and methods for producing
ATE549358T1 (de) Neuer anti-plgf-antikörper
WO2004003147A3 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
WO2003035847A3 (en) Il-13 mutein proteins, antibodies, compositions, methods and uses
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
WO2004093808A3 (en) Novel tumor-associated antigens
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
WO2004016230A3 (en) Identification of the endothelial receptor for the angiostatin kringle-5
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
WO2005094355A3 (en) Methods for altering protein production rates
WO2001004143A3 (en) Prostase vaccine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1507859

Country of ref document: EP